Back to top

earnings-consensus: Archive

Zacks Equity Research

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

ARQTNegative Net Change

Zacks Equity Research

Wall Street Analysts Predict a 41.36% Upside in CI&T (CINT): Here's What You Should Know

The consensus price target hints at a 41.4% upside potential for CI&T (CINT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CINTNegative Net Change

Zacks Equity Research

Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 130.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

FHTXPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe DoubleDown Interactive (DDI) Could Rally 99.48%: Here's is How to Trade

The consensus price target hints at a 99.5% upside potential for DoubleDown Interactive (DDI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

DDINegative Net Change

Zacks Equity Research

Wall Street Analysts Predict a 35.8% Upside in Ranpak Holdings (PACK): Here's What You Should Know

The mean of analysts' price targets for Ranpak Holdings (PACK) points to a 35.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

PACKPositive Net Change

Zacks Equity Research

Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet

The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

AMRXNegative Net Change

Zacks Equity Research

Does BioLife Solutions (BLFS) Have the Potential to Rally 25.6% as Wall Street Analysts Expect?

The consensus price target hints at a 25.6% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BLFSPositive Net Change

Zacks Equity Research

Wall Street Analysts Think Adeia (ADEA) Could Surge 27.58%: Read This Before Placing a Bet

The mean of analysts' price targets for Adeia (ADEA) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ADEANegative Net Change

Zacks Equity Research

Wall Street Analysts Think Beyond (BYON) Could Surge 59.75%: Read This Before Placing a Bet

The mean of analysts' price targets for Beyond (BYON) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Wall Street Analysts Think Alkami (ALKT) Could Surge 50.64%: Read This Before Placing a Bet

The consensus price target hints at a 50.6% upside potential for Alkami (ALKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ALKTPositive Net Change

Zacks Equity Research

Wall Street Analysts See an 115.23% Upside in Xperi (XPER): Can the Stock Really Move This High?

The mean of analysts' price targets for Xperi (XPER) points to an 115.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

XPERPositive Net Change

Zacks Equity Research

Wall Street Analysts Predict a 33.1% Upside in Potbelly (PBPB): Here's What You Should Know

The consensus price target hints at a 33.1% upside potential for Potbelly (PBPB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

PBPBPositive Net Change

Zacks Equity Research

How Much Upside is Left in Globale Online (GLBE)? Wall Street Analysts Think 36.83%

The mean of analysts' price targets for Globale Online (GLBE) points to a 36.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

GLBENegative Net Change

Zacks Equity Research

How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%

The mean of analysts' price targets for Inventiva (IVA) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

IVAPositive Net Change

Zacks Equity Research

Wall Street Analysts See a 98.59% Upside in Anika (ANIK): Can the Stock Really Move This High?

The consensus price target hints at a 98.6% upside potential for Anika (ANIK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ANIKNegative Net Change

Zacks Equity Research

Earnings Preview: Shoe Carnival (SCVL) Q2 Earnings Expected to Decline

Shoe Carnival (SCVL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SCVLPositive Net Change

Zacks Equity Research

Torrid Holdings (CURV) Expected to Beat Earnings Estimates: Should You Buy?

Torrid Holdings (CURV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CURVPositive Net Change AEONegative Net Change

Zacks Equity Research

Analysts Estimate Lululemon (LULU) to Report a Decline in Earnings: What to Look Out for

Lululemon (LULU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LULUNegative Net Change

Zacks Equity Research

Does Electromed (ELMD) Have the Potential to Rally 38.6% as Wall Street Analysts Expect?

The mean of analysts' price targets for Electromed (ELMD) points to a 38.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ELMDPositive Net Change

Zacks Equity Research

Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect?

The mean of analysts' price targets for AxoGen (AXGN) points to a 53.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

AXGNNo Net Change

Zacks Equity Research

Wall Street Analysts Think SunOpta (STKL) Could Surge 57.73%: Read This Before Placing a Bet

The consensus price target hints at a 57.7% upside potential for SunOpta (STKL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

STKLPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe VAREX IMAGING (VREX) Could Rally 46.29%: Here's is How to Trade

The consensus price target hints at a 46.3% upside potential for VAREX IMAGING (VREX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

VREXPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe Peloton (PTON) Could Rally 34.77%: Here's is How to Trade

The consensus price target hints at a 34.8% upside potential for Peloton (PTON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

PTONNegative Net Change

Zacks Equity Research

Wall Street Analysts Believe O-I Glass (OI) Could Rally 28.58%: Here's is How to Trade

The consensus price target hints at a 28.6% upside potential for O-I Glass (OI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

OINegative Net Change

Zacks Equity Research

Wall Street Analysts See a 30.37% Upside in Cars.com (CARS): Can the Stock Really Move This High?

The consensus price target hints at a 30.4% upside potential for Cars.com (CARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CARSPositive Net Change